Published Date : Aug 08, 2016
ALBANY, NY, Aug 08, 2016: MarketResearchReports.biz has added a new report, titled ‘Global Dermatology Market To 2022 - Innovative Pipeline And Increasing Uptake Of Biologics To Diversify Treatment Options And Drive Strong Growth’ to its offering. This study presents an in-depth evaluation on the market for dermatology products. It also aids in providing a clear picture of the clinical and commercial landscape of the market.
A detailed reports of the dynamics impacting the growth of this market has been presented in the report. The commercially available products in the market have been detailed and insights into the key commercial assets and the composition of this market also form an integral part of this study.
As per the study, the global dermatology market stood at $20.0 bn in 2015 and is poised to touch $33.7 bn by 2022, rising at a 7.73% CAGR from 2015 to 2022. The introduction section of the study presents the definition of dermatology. This part also encapsulates insights into all the dermatological disorders, with a specific focus on the three most common type of diseases, namely psoriasis, acne vulgaris, and atopic dermatitis.
Dermatology is a branch of medicine that deals with hair, nails, and skin, and their related diseases. Dermatological conditions are regarded as amongst the most common kinds of disorders globally, with around one-third of the population in the U.S. alone suffering from at least one kind of active skin disorder.
The treatment options utilized for all these diseases have been analyzed under the next section of the study. The treatment options available in the global dermatology market are retinoids, calcineurin inhibitors, systemic immunosuppressive agents, hormonal therapy, biologics, antihistamines, and moisturizers.
In the following section of the report, the top marketed products in the dermatology market have been presented. These include Humira (adalimumab), Remicade (infliximab), Enbrel (etanercept), Stelara (ustekinumab), Neoral (cyclosporine), Protopic (tacrolimus), and Elidel (pimecrolimus), among others.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/725316
Moving further, an assessment of the pipeline landscape of the global dermatology market has been presented. This section encapsulates the molecular types and molecular targets present in the pipeline. It also elaborates on the clinical trials taking place in the market for dermatology. As per the report, there are 801 dermatology products in the pipeline. Of these, biologics represented a share of 37% in 2015.
The factors fuelling and restraining the growth of the market come next in the report. The increasing commercial and clinical success of biologics for the treatment of psoriasis is amongst the key factors fuelling the growth of the market. In addition, the increasing evaluation of disease pathways of a number of dermatological conditions has resulted in a rising interest from various pharmaceutical players dominant in the market. This is further driving the development of the overall market for dermatology.
In addition, the increasing proliferation of lucrative late-stage products will also positively impact the development of this market. Furthermore, the increasing adoption of recently approved premium biologics will also provide impetus to the growth of the global dermatology market.
The last section of the report presents the positioning of the top companies in the market. These companies have been evaluated on the basis of their pipeline portfolio and marketed products.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org